A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Prelude Therapeutics
Takeda
Tempus AI
Incyte Corporation
Actym Therapeutics, Inc.
Pfizer
Telix Pharmaceuticals (Innovations) Pty Limited
Eli Lilly and Company
Elevation Oncology
Seagen Inc.
Pfizer
Aminex Therapeutics, Inc.
BioNTech SE
Bristol-Myers Squibb
Janssen Pharmaceutical K.K.
Adaptimmune
ADC Therapeutics S.A.
Viome
pharmaand GmbH
Merck Sharp & Dohme LLC
Fate Therapeutics
Genmab
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Boston Scientific Corporation
Merrimack Pharmaceuticals
Amgen
Auron Healthcare GmbH
GlaxoSmithKline